ACET

MKT CAP:$76M

Adicet Bio, Inc.

Market Cap

$76M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$8.05-$0.77 (-8.67%)

Apr 21, 2026

Company Details

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-l...

CEO

Chen Schor

IPO Date

Jan 26, 2018

Website

www.adicetbio.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$117M

EPS (Diluted)

-$17.98

Free Cash Flow

-$97M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 5, 2026

PENDING

FY 2025

Mar 12, 2026

$0EPS -$16.95

Q4 2025

Mar 12, 2026

$0EPS -$2.94

Q3 2025

Nov 5, 2025

$0EPS -$4.64

Q2 2025

Aug 7, 2025

$0EPS -$5.44

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$25M	$25M	$5M
Q2 22	$0	$0	-$23M
Q3 22	$0	$0	-$23M
Q4 22	$0	$0	-$32M
Q1 23	$0	$0	-$33M
Q2 23	$0	$0	-$35M
Q3 23	$0	$0	-$52M
Q4 23	$0	$0	-$32M
Q1 24	$0	-$2M	-$31M
Q2 24	$0	$0	-$33M
Q3 24	$0	$0	-$33M
Q4 24	$0	$0	-$31M
Q1 25	$0	$0	-$30M
Q2 25	$0	$0	-$32M
Q3 25	$0	$0	-$28M
Q4 25	$0	-$1M	-$32M

Valuation

Quarter	P/S	P/E
Q1 22	325.5x	—
Q2 22	271.7x	—
Q3 22	329.1x	—
Q4 22	209.5x	—
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	—	—
Q1 24	—	—
Q2 24	—	—
Q3 24	—	—
Q4 24	—	—
Q1 25	—	—
Q2 25	—	—
Q3 25	—	—
Q4 25	—	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	$4M	$1M
Q2 22	-$15M	-$18M
Q3 22	-$15M	-$20M
Q4 22	-$19M	-$25M
Q1 23	-$24M	-$26M
Q2 23	-$25M	-$26M
Q3 23	-$21M	-$22M
Q4 23	-$23M	-$24M
Q1 24	-$23M	-$23M
Q2 24	-$23M	-$24M
Q3 24	-$22M	-$22M
Q4 24	-$24M	-$24M
Q1 25	-$25M	-$27M
Q2 25	-$27M	-$27M
Q3 25	-$22M	-$23M
Q4 25	-$21M	-$21M

Capital Expenditures

Quarter	CapEx
Q1 22	$3M
Q2 22	$3M
Q3 22	$5M
Q4 22	$6M
Q1 23	$2M
Q2 23	$2M
Q3 23	$906.0K
Q4 23	$136.0K
Q1 24	$239.0K
Q2 24	$302.0K
Q3 24	$401.0K
Q4 24	$176.0K
Q1 25	$1M
Q2 25	$47.0K
Q3 25	$209.0K
Q4 25	$10.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	+727.7%	+16.8%
Q2 22	-100.0%	+45.2%
Q3 22	-100.0%	+34.1%
Q4 22	-100.0%	+50.2%
Q1 23	-100.0%	+64.3%
Q2 23	—	+53.7%
Q3 23	—	+127.4%
Q4 23	—	+0.0%
Q1 24	—	-7.4%
Q2 24	—	-5.8%
Q3 24	—	-36.6%
Q4 24	—	-2.6%
Q1 25	—	-3.2%
Q2 25	—	-1.4%
Q3 25	—	-15.7%
Q4 25	—	+3.7%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$4M	17.4%
Q2 22	$4M	—
Q3 22	$4M	—
Q4 22	$4M	—
Q1 23	$5M	—
Q2 23	$5M	—
Q3 23	$6M	—
Q4 23	$5M	—
Q1 24	$6M	—
Q2 24	$6M	—
Q3 24	$7M	—
Q4 24	$4M	—
Q1 25	$3M	—
Q2 25	$3M	—
Q3 25	$3M	—
Q4 25	$6M	—

OpEx Breakdown

Quarter	R&D	G&A
Q1 22	$13M	$7M
Q2 22	$16M	$7M
Q3 22	$17M	$6M
Q4 22	$25M	$7M
Q1 23	$27M	$7M
Q2 23	$28M	$7M
Q3 23	$26M	$7M
Q4 23	$25M	$7M
Q1 24	$24M	$7M
Q2 24	$26M	$7M
Q3 24	$26M	$7M
Q4 24	$23M	$7M
Q1 25	$23M	$7M
Q2 25	$28M	$4M
Q3 25	$23M	$5M
Q4 25	$25M	$7M

Revenue Segments

Quarter

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$278M	$0	$278M
Q2 22	$261M	$0	$261M
Q3 22	$283M	$0	$283M
Q4 22	$258M	$0	$258M
Q1 23	$232M	$0	$232M
Q2 23	$205M	$0	$205M
Q3 23	$183M	$0	$183M
Q4 23	$160M	$0	$160M
Q1 24	$248M	$0	$248M
Q2 24	$224M	$0	$224M
Q3 24	$105M	$97M	$202M
Q4 24	$56M	$120M	$176M
Q1 25	$28M	$122M	$150M
Q2 25	$35M	$90M	$125M
Q3 25	$29M	$74M	$103M
Q4 25	$39M	$120M	$159M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	3M	+35.5%	+76.1%
Q2 22	3M	-12.8%	+25.9%
Q3 22	3M	+3.9%	+30.6%
Q4 22	3M	+0.0%	+22.8%
Q1 23	3M	+3.1%	-6.5%
Q2 23	3M	+0.0%	+7.2%
Q3 23	3M	+0.1%	+3.2%
Q4 23	3M	+0.1%	+3.3%
Q1 24	5M	+83.7%	+84.1%
Q2 24	6M	+14.6%	+111.0%
Q3 24	6M	+0.2%	+111.4%
Q4 24	5M	-3.3%	+104.2%
Q1 25	6M	+3.6%	+15.2%
Q2 25	6M	+0.0%	+0.5%
Q3 25	6M	+0.0%	+0.3%
Q4 25	7M	+21.1%	+25.5%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$290.6K	86
Q2 22	$0	86
Q3 22	$0	86
Q4 22	$0	132
Q1 23	$0	132
Q2 23	$0	132
Q3 23	$0	132
Q4 23	$0	143
Q1 24	$0	143
Q2 24	$0	143
Q3 24	$0	143
Q4 24	$0	152
Q1 25	$0	152
Q2 25	$0	152
Q3 25	$0	152
Q4 25	$0	200K

Revenue / Employee